Positive Final Results, Phase 2 Dose-Ranging Study Of Zerenex For Hyperphosphatemia Treatment In Patients With End-stage Renal Disease
Fri, 30 Jun 2006 06:00 AM EST
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX) today announced positive final results from the Phase 2multi- center study entitled: "A randomized, double-blind,placebo-controlled, dose ranging study of the effects of Zerenex(TM) onserum phosphate in patients with end stage renal disease (ESRD). [click link for full article] ...
Related Topics
- End-stage Renal Disease
- Kidney Diseases
- Liver Disease
- Pulmonary Fibrosis
- Kidney Failure
- Kidney Disease
- Hodgkin's Disease
- CHF
- Kidney Cancer
- Emphysema
- ESRD
- Disease models
- Death And Dying
- Vascular Disease
- Chronic Obstructive Pulmonary Disease
- Periodontal Disease
- Pancreatic Cancer
- Cirrhosis
- Cardiovascular Diseases And Disorders
- Renal Cell Cancer

Not Signed In -


